HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Compass Therapeutics Files Definitive Proxy Statement

Created at 4 Jun · 2:47 AM3 sources
IN SHORT

Compass Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) with the SEC on June 3. The filing provides details for the company's annual shareholder meeting, including information on executive compensation and director nominations.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Who's Involved

Compass Therapeutics, Inc.
Company filing DEF 14A proxy statement
SEC
U.S. securities regulator receiving the filing

↳ Why This Matters

Proxy statements provide crucial transparency into corporate governance, executive pay, and board composition, enabling shareholders to make informed voting decisions and holding management accountable.

Key facts

  • Compass Therapeutics, Inc. filed a DEF 14A proxy statement on June 3.
  • The filing relates to the company's annual shareholder meeting.
  • It contains information on executive compensation and director nominations.

Compass Therapeutics, Inc. submitted its definitive proxy statement (DEF 14A) to the Securities and Exchange Commission (SEC) on June 3. This filing is a prerequisite for the company's annual shareholder meeting, providing comprehensive details on corporate governance. Shareholders can review information regarding executive compensation, the proposed slate of directors, and any other matters requiring a shareholder vote. The DEF 14A ensures shareholders are informed to make educated decisions during the voting process at the annual meeting.

Frequently asked questions

A DEF 14A is a definitive proxy statement filed with the SEC by public companies before their annual shareholder meetings. It details executive compensation, board nominations, and shareholder proposals.

It includes information on director nominees, executive compensation packages, auditor ratification, and any other proposals to be voted on by shareholders.

Compass Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies.

What Happens Next

01Shareholders will review the proxy statement in preparation for the annual meeting.
02Compass Therapeutics, Inc. will hold its annual shareholder meeting.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • New Product Summary: Initial Listing of Fifty-Five (55) Single Stock Futures Contracts — Effective July 27, 2026
    27 Jul · 4:32 PM
  • New Product Summary: Initial Listing of Twenty-Two (22) Micro Single Stock Futures Contracts - Effective July 27, 2026
    27 Jul · 4:11 PM
  • Initial Listing of Additional Event Contract Swaps on Pro Golf Tournaments
    9 Jul · 9:41 AM

How It Developed

4 Jun · 2:15 AM
Amesite Inc. filed its DEF 14A filing on June 3, detailing its executive compensation and corporate governance.
Investing.com via PiQSuite

Sources

T1
Form DEF 14A Amesite Inc. For: 3 Junem.piqsuite.com
T1
Form DEF 14A Tyra Biosciences Inc For: 3 Junem.piqsuite.com
T1
Form DEF 14A Compass Therapeutics, Inc. For: 3 Junem.piqsuite.com

Related Stories

SK Hynix $28B ADR bookbuild closes Wednesday amid strong demand
8 Jul · 7:57 AM
Workspace urges investors to block Saba's 'destructive' property sell-off plan
9 Jul · 6:55 AM
Zhipu AI Shares Rise After Lockup Expiry Amid Investor Support
8 Jul · 8:25 PM
AI and SpaceX Wealth Fuels New Luxury Spending Habits
8 Jul · 10:06 AM
Honeywell Technologies raises 2026 profit targets after reverse stock split
8 Jul · 9:08 PM